A Phase 2 Study With Combination Chemotherapy (Gemcitabine and Nab-Paclitaxel), Chemokine (C-X-C) Motif Receptor 4 Inhibitor (BL-8040), and Immune Checkpoint Blockade (Cemiplimab) in METastatic Treatment naïve PANCreas Adenocarcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT04543071

Title field or adapter rule

{'original_value': 'A Phase 2 Study With Combination Chemotherapy (Gemcitabine and Nab-Paclitaxel), Chemokine (C-X-C) Motif Receptor 4 Inhibitor (BL-8040), and Immune Checkpoint Blockade (Cemiplimab) in METastatic Treatment naïve PANCreas Adenocarcinoma', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:25.322022+00:00

Published At

2026-09-21T00:00:00+00:00

Record Updated At

2026-09-21

Source Retrieved At

2026-10-31T22:17:56.788771+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Pancreatic Cancer", "Adenocarcinoma of the Pancreas", "Adenocarcinoma"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-09-21", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT04543071"

protocolSection.identificationModule.officialTitle

"A Phase 2 Study With Combination Chemotherapy (Gemcitabine and Nab-Paclitaxel), Chemokine (C-X-C) Motif Receptor 4 Inhibitor (BL-8040), and Immune Checkpoint Blockade (Cemiplimab) in METastatic Treatment na\u00efve PANCreas Adenocarcinoma"

protocolSection.statusModule.overallStatus

"ACTIVE_NOT_RECRUITING"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Pancreatic Cancer (protocolSection.conditionsModule.conditions)
• Adenocarcinoma of the Pancreas (protocolSection.conditionsModule.conditions)
• Adenocarcinoma (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Motixafortide, Cemiplimab, Gemcitabine, Nab-Paclitaxel'], 'description': '1.25 mg/kg subcutaneous (SC) monotherapy daily for 5 days during priming, followed by twice weekly', 'name': 'Motixafortide', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Motixafortide, Cemiplimab, Gemcitabine, Nab-Paclitaxel'], 'description': '350 mg intravenous (IV) once every 21 days', 'name': 'Cemiplimab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Motixafortide, Cemiplimab, Gemcitabine, Nab-Paclitaxel'], 'description': '1000 mg/m2 IV on days days 1, 8, 14 (every 28 days)', 'name': 'Gemcitabine', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Motixafortide, Cemiplimab, Gemcitabine, Nab-Paclitaxel'], 'description': '125 mg/m2 IV on days 1, 8, 14 (every 28 days)', 'name': 'Nab paclitaxel', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Motixafortide (protocolSection.armsInterventionsModule.interventions[].name)
• Cemiplimab (protocolSection.armsInterventionsModule.interventions[].name)
• Gemcitabine (protocolSection.armsInterventionsModule.interventions[].name)
• Nab paclitaxel (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.